"In 2022, we were focused on advancing B-VEC toward approval and getting commercially prepared for a potential launch this year, and I thank the entire Krystal team for their dedication and perseverance in helping us achieve our objectives," said Krish S. Krishnan, Chairman and CEO of Krystal Biotech, Inc. He added, "Our focus in 2023 will be on advancing our pipeline and demonstrating the breadth of our gene delivery platform. We plan to have ASTRA, our second manufacturing facility, operational early this year which will enable us to advance our pipeline products in a timely manner."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KRYS:
- Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
- Krystal Biotech CEO sells $4.04M in common stock
- Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
- EC grants Krystal Biotech orphan designation for KB407 for CF treatment
- Krystal Biotech PDUFA delay ‘a minor setback,’ says Chardan